20-22 August 2018

San Francisco, CA

Register by Friday, June 15 to Save $400

Day One
Tuesday 21 August, 2018

Day Two
Wednesday 22 August, 2018

08.50
Chair’s Opening Remarks

Identifying the “Idiopathic” of IPF to Drive Curative IPF Drug Development

09.00
Translational Modeling of Profibrotic & Aberrant Regenerative Mechanisms in IPF

  • Cory Hogaboam Professor of Medicine, Ceders-Sinai Medical Center

Synopsis

  • Dissecting the pathology of IPF as a disease of enhanced fibrosis and impaired lung regeneration
  • Proving how translational modeling in humanized immunodeficient mice facilitates exploration of both mechanisms in IPF
  • Describing putative therapeutic strategies that target both fibrosis and lung regeneration

Outside of Targeting Fibroblasts: Therapeutically Promoting Regeneration

09.30
Restoring Balance in IPF: Development of a Compound Targeting Both Epithelial Cell Survival as well as Myofibroblast Destruction for Improved Therapeutic Response

Synopsis

  • Outlining a novel approach beyond inhibition of fibroblast activation
  • Demonstrating the Cav1 pathway as allowing for restoring survival signals that have become dysregulated in IPF
  • Discussing the preservation of epithelial cell survival as critical in enabling restoration of  lung function

10.00
Morning Refreshments & Networking

11.00
Innovative RNA Based Therapeutics as a Modality for the Effective Treatment of Multiple Fibrotic Conditions

Synopsis

  • Understanding miRNAs as regulators of systems biology
  • Outlining miR-29 as an anti-fibrotic miRNA
  • Showing miR-29 as a therapeutic target in multiple fibrotic indications
  • Presenting the development of an inhaled oligonucleotide

11.30
Developmental Program Identifying siRNA HSP47 as a New Therapeutic Strategy for IPF – Comprehensive Model Validation & Therapeutic Evaluation

  • Wenbin Ying Executive Vice President, Nitto BioPharma

Synopsis

  • Highlighting new target engaged in fibrotic disease development and progress
  • Demonstrating novel lipid nanoparticle for in vivo siRNA delivery which show robust anti-fibrotic activities
  • Outlining results of efficacy tested in the fully validated bleomycin rat model in the clinically relevant scenario and treatment regimen
  • Showing results from pulmonary function assessment included in the therapeutically efficacy evaluation

12.00
Lunch & Networking

Navigating the Rationale, Practical & Clinical Success of Combination Therapies

13.00
Lessons Learnt from Combination Therapies with Pirfenidone

  • Joe Arron Senior Director, Immunology Research, Genentech

Synopsis

  • Outlining rationale from combinations of pirfenidone in clinical trials with two new interventions
  • Analyzing decisions made
  • Benchmarking lessons learnt

13.30
Panel Discussion: Assessing the Current Drug Landscape to Understand Combinations as Successful Treatment Options Within IPF

  • Seth Porter Vice President, Fibrosis Therapeutics, FibroGen
  • Joe Arron Senior Director, Immunology Research, Genentech
  • John Moran Chief Medical Officer, Prometic Biosciences

Synopsis

  • Beyond IPF – is there potential for combinations with candidate targeting other disease areas, such as lung cancer?
  • Addressing tolerability and dosage concerns when drugs are given in combination in the context of an IPF patient
  • What is the future of IPF in terms of product development?

Robustly & More Confidently Moving Through Clinical Development: Showcasing & Analyzing Results

14.00
Targeting the Angiotensin AT2-receptor for the Treatment of Orphan Fibrotic Diseases

Synopsis

  • Describing the biology of the angiotensin AT2-receptor
  • Understanding the anti-fibrotic mechanism of action of the AT2-receptor agonist C21
  • Detailing the clinical development of C21

14.30
Afternoon Refreshments & Networking

15.30
UCHL1 – A Deubiquitylating Enzyme with Fundamental Roles in the Regulation of Pro-Fibrotic Signalling Pathways

  • Anne Phelan Senior Vice President & Head of Discovery Research, Mission Therapeutics

Synopsis

  • Highlighting the key role of deubiquitylating enzymes in the regulation of protein homeostasis, complex formation and turnover or degradation
  • Outlining how UCHL1 is recognized as a key modulator of components of the TGFβ, AKT and ERK pro-fibrotic signalling cascades across a range of tissue types
  • Demonstrating how the expression of UCHL1 has been shown to be upregulated in lung samples derived from patients with IPF and COPD; and that UCHL1 gain-of-function polymorphism is associated with Akt mediated lung fibrosis pathologies and PAH
  • Sharing the clinical potential of a potent and selective inhibitor of UCHL1 in the treatment of fibrotic lung diseases

16.00
Evaluation of Pentraxin-2 (PRM-151) in IPF Clinical Trial Settings

  • Rick Jack President, Chief Operations Officer & Chief Scientific Officer, Promedior

Synopsis

  • Overcoming challenges in the translational steps between discovery and phase 2 Clinical Trial
  • Linking phase 1 design and results with phase 2 design
  • Translating PRM-151 into the clinic: how non-clinical and clinical data from IPF clinical trials can guide other fibrosis therapeutic applications

16.30
Chair’s Closing Remarks